NRx Pharmaceuticals Outlines Potential Paths To Revenue And Profitability In 2025; New Shareholder Update Highlights Potential 2024 Revenue From HOPE Therapeutics-Branded Clinics, 2025 Revenue From Sales Of NRX-100 (IV Ketamine) Pending FDA Approval,...
NRx Pharmaceuticals Outlines Potential Paths To Revenue And Profitability In 2025; New Shareholder Update Highlights Potential 2024 Revenue From HOPE Therapeutics-Branded Clinics, 2025 Revenue From Sales Of NRX-100 (IV Ketamine) Pending FDA Approval,...
NRx藥品公司概述了2025年可能獲得營業收入和盈利的潛在途徑；新股東更新突出了HOPE治療品牌診所2024年的潛在營業收入，以及待FDA批准的NRX-100（IV****）銷售所能獲得的2025年營業收入……
NRx Pharmaceuticals Outlines Potential Paths To Revenue And Profitability In 2025; New Shareholder Update Highlights Potential 2024 Revenue From HOPE Therapeutics-Branded Clinics, 2025 Revenue From Sales Of NRX-100 (IV Ketamine) Pending FDA Approval, And 2025 Revenue From NRX-101 For Suicidal Bipolar Depression And Akathisia
NRx藥品公司概述了2025年實現收入和盈利的潛在途徑。新的股東更新強調了HOPE治療品牌診所2024年的潛在收入，NRX-100（IV****）待FDA批准後的2025年銷售收入，以及NRX-101用於自殺性雙相障礙和躁動症的2025年收入。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。